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Background: Cochleotoxicity following the treatment with platinum-based
chemotherapy is well documented. The potential for vestibulotoxicity is still unclear.
This scoping review examined the extent of current research literature, summarized
research findings and identified research gaps regarding vestibular-related adverse
effects associated with platinum-based chemotherapy in survivors of cancer.
Methods: Inclusion criteria followed the PICO principles: Participants, adult, and
pediatric cancer patients of any cancer type; Intervention, platinum-based chemotherapy
(such as cisplatin, carboplatin, and oxaliplatin); Control, none or any; Outcomes,
vestibular-related adverse effects. English language articles published since 1978 were
retrieved. Seventy-five eligible studies were identified from a systematic literature search,
and relevant data were charted, collated, and summarized.
Results: Testing for vestibulotoxicity predominately featured functional evaluation of the
horizontal semicircular canal using the caloric and rotational tests. The rate of abnormal
vestibular function test results after chemotherapy administration varied from 0 to 50%.
The results of objective testing did not always correspond to patient symptoms. There
is tentative support for patients with pre-existing loss of vestibular function to be more
likely to experience vestibular toxicity after dosing with cisplatin.
Conclusions: A number of studies reported significant evidence of vestibular toxicities
associated with platinum-based chemotherapy, especially cisplatin. This scoping review
emphasizes that vestibular toxicity needs more attention and comprehensive evaluation.
Specifically, studies that analyse cumulative dose of platinum-based chemotherapy,
affected sites of lesion in vestibular end organs, and the correlation and temporal patterns
of cochlear and vestibular toxicity are needed.
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INTRODUCTION
More than 15.5 million cancer survivors are living in the
United States alone, and this number is set to increase to 20
million by 2026 because of advances in early detection, effective
treatment, and the aging and growth of the population (1). As a
consequence of these increased survival rates, more attention is
being given to improvements in long-term effects, health-related
quality of life, and follow up care after cancer treatment (2).
Platinum-based chemotherapy is an effective antineoplastic
intervention that is used for a variety of human malignancies
including testicular, ovarian, bladder, head and neck, and non-
small cell lung cancer (3). Irreversible hearing loss following the
treatment with platinum-based drugs, especially cisplatin (which
causes permanent hearing loss of variable degree in 40–80% of
treated patients) is well documented (4). Long-term monitoring
of cochleotoxic effects of platinum-based chemotherapy is
therefore advised (5) and implemented in clinical practice (6).
There is also some evidence that cisplatin has long-term retention
in the cochlea (7). Given that the auditory and vestibular
organs of the inner ear share the same blood, nerve and fluid
supplies, this finding has potential implications for functions of
both compartments (8). However, there are some differences in
physiology and function between the cochlear and vestibular end
organs, and these may mediate the impact of toxicity associated
with platinum compounds. Specific areas of interest include the
role of the stria vascularis in the cochlea (9), as no analogous
structure is present in the vestibular labyrinth, and the possible
role of transporters such as megalin (10). There is a strong
potential for cochlear toxicity to be accompanied by vestibular
toxicity in patients receiving platinum-based chemotherapy.
However, clinical reports of inner ear toxicity are limited largely
to auditory symptoms.
The vestibular organs of the inner ear play an important role
in the complex and dynamic human balance system (11). The
peripheral vestibular system in the inner ear consists of five
sensory organs: three semicircular canals (horizontal, anterior,
and posterior) and two otolith organs (saccule and utricle) on
each side (11). The integration occurs at the central nervous
system giving efferent fibers to vestibulo-ocular, and vestibulo-
spinal pathways (11). No clinical test can directly measure the
inner ear function of the vestibular periphery. Instead, inferences
must be made about vestibular function on the basis of the
performance of downstream processes especially the vestibulo-
ocular reflex (VOR). In the wider context, the balance system
covers the spatial orientation of the whole body, which is
maintained by the integration of visual, somatosensory, and
vestibular inputs to the central nervous system (11). While the
vestibular function refers to the health of the vestibular portion
of the inner ear, balance function is not restricted to a vestibular
component alone.
The potential for vestibular toxicity is still unclear, though
clinical data suggests it is problematic (12, 13). There are
a number of potential explanations for why vestibulotoxicity
from platinum-based chemotherapy is less frequently described
than auditory symptoms. First, some of the clinical signs
and patient-reported symptoms may be underappreciated by
clinicians. Notably, drug-induced vestibular loss may affect
both ears symmetrically and gradually resulting in insidious
disequilibrium, postural imbalance, and oscillopsia (illusion
of movement of the visible world during head movement).
These symptoms are less likely to undergo clinical assessment,
compared with the sudden onset of spinning vertigo such
as benign paroxysmal positional vertigo (BPPV), vestibular
neuritis and Meniere’s disease (14, 15). Secondly, vestibular
organ dysfunction may be masked by central compensation or
substitution by vision and proprioception, obscuring vestibular
damage compared with the more noticeable cochlear damage
(16). Thirdly, platinum-based chemotherapy agents are used
in combination with several other drugs, and some of
these may have ototoxic properties such as aminoglycoside
antibiotics (17) and loop diuretics (18). Thus, the specific
attribution of vestibulotoxicity to platinum-based compounds
may be obscured. Finally, non-specific symptoms of imbalance
may be attributed to underlying cancer diseases and general
deconditioning of patients during and after treatment such as
dehydration, nausea and vomiting, chronic fatigue, and anemia.
Vestibular dysfunction can have a considerable impact
on quality of life (19) and substantial economic burden on
individuals and society (20). Recent evidence suggests that
balance problems such as falls andmobility disability in survivors
of cancer aremore common than amongst the general population
(21–23). This is of great importance as falling is a leading cause
of morbidity and mortality in the community population (24).
Therefore, there is a need to increase awareness of balance
problems in this vulnerable group of cancer patients in order to
provide accurate prevention and intervention measures (25).
While systematic review methodology seeks to collate all
evidence in order to address a specific research question, scoping
review methodology aims to map the key concepts underpinning
a research area and the main sources and types of evidence
available (26). A scoping review can be undertaken as a stand-
alone project in its own right, especially where an area has not
previously been reviewed in a comprehensive manner (26). This
scoping review examined the extent of current research literature
on vestibular-related adverse effects associated with platinum-
based chemotherapy in survivors of cancer to summarize
research findings and identify research gaps.
METHOD
The method of this scoping review is largely based on the steps
of the framework proposed by Arksey and O’Malley (26): (1)
identify relevant studies, (2) select studies, (3) chart the data,
(4) collate, summarize and report the results, and (5) consult
clinical experts. Study details were registered on PROSPERO
(CRD42017083576).
Identify Relevant Studies
The following databases were searched: Medline, EMBASE,
TOXLINE, IPA (International Pharmaceutical Abstracts),
Science Citation Index-Expanded, ProQuest Dissertations &
Theses A&I, ClinicalTrials.gov, Cochrane Central Register of
Controlled Trials (CENTRAL), and International Clinical Trials
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Registry Platform (ICTRP). Gray literature was also considered
through the Database of Adverse Event Notifications [Australia],
Drug Safety Update [UK], European Public Assessment Reports
via European Medicines Agency [Europe], and Medwatch
[USA]. The steps followed the Cochrane Handbook (27)
and the Cochrane Methodological Expectations of Cochrane
Intervention Reviews (MECIR) (28) for conducting the search,
the PRISMA guideline (29) for reporting the search, and the
PRESS guideline for peer-reviewing the search strategies (30).
The search strategy followed recommendations for optimizing
the search syntax to identify adverse effects (31–34). Standardized
terms and keywords were combined in the search for concepts of
platinum-based chemotherapy and vestibular toxicity. Keywords
were collected through expert opinions, literature reviews,
controlled vocabulary (Medical Subject Headings = MeSH and
Excerpta Medica Tree = EMTREE), and reviewing preliminary
search results. Filters for electronic databases were applied where
possible to retrieve articles in the English language, with human
participants, and time of publication since 1978 which is the time
that cisplatin, the first drug in the platinum-based chemotherapy
group, was approved by Food and Drug Administration (FDA)
for human use (3). We limited our search to the English language
because of resource constraints. The search strategies are
reported in Appendix 1.
Study Selection
Two screening steps were undertaken independently by two
authors. The first step checked that each title and abstract was
within the scope of research question. Examples of “out of scope”
decisions were where there was no mention of platinum-based
chemotherapy, in vitro or in vivo studies, or review articles
or conference papers. The second step of full text screening
considered eligible records that contained data pertinent to the
subject of the review, specifically vestibular-related symptoms
and/or test results in adults and/or pediatric cancer patients
undergoing platinum-based chemotherapy (such as cisplatin,
carboplatin, and oxaliplatin) in any cancer types (either alone
or in combination with other treatments such as radiotherapy
or surgery). Eligible studies were randomized controlled trials
(RCTs), non-randomized controlled trials, observational studies,
cross-sectional studies, cohort studies, case control studies, case
series, and case reports. Discrepancies were resolved through
discussion and a third reviewer was consulted whenever a
consensus was not reached. Literature saturation was further
accomplished by additional hand searching of the reference lists
of all included studies and also those of the excluded review
articles.
Charting the Data
Pre-specified data items included year, study design, participant
demographics and characteristics, sample size, cancer treatment
intervention, drug dose, and patient evaluation. These data items
provided useful information about the scope and details of
each record, enabling the authors to look for common themes
and to identify possible gaps in the literature. Multiple reports
pertaining to a single study were treated as one, but data
extraction considered information presented in all records. Data
from each included study was independently extracted by two
clinical experts on the team (PP, an otorhinolaryngologist and
DB, an audiologist). Discrepancies were identified and resolved
through discussion.
Collating, Summarizing and Reporting the
Results
For the purpose of understanding key concepts in this literature,
thematic analysis was conducted following article review to
summarize the literature into themes by the two members of
the research team (PP and DB). The authors independently
reviewed the charted final data set and identified themes, and
then met to discuss possible thematic structures, using the
criteria that themes should be important clinical aspects and
should adequately represent all of the records. Specific themes
identified were objective tests of vestibular and/or balance
function, patients’ symptoms, physical examination, associated
factors, and general considerations. The authors then grouped
all studies according to these themes. The content of individual
records does not necessarily fall exclusively in one theme or
another; hence, the records could contribute to more than one
theme. Research findings were summarized and research gaps
were identified.
Clinical Expert Consultation
Two clinical experts on the team (AK, an otorhinolaryngologist
and PMP, an oncologist) reviewed the themes and supporting
evidence of the results.
RESULTS
A summary of the study selection processes with the reasons
for exclusion is represented in Figure 1. A total of 2,620 records
were retrieved from the electronic databases and five additional
articles were found by manually searching reference lists of those
records included in the full text screening. Most records were
excluded because they did not mention vestibular side effects, did
not mention platinum-based chemotherapy, or were in vitro or
in vivo studies. Overall, 75 individual studies were included for
data extraction. The sample size of the study participants varied
from 1 to 952. The age reported ranged from 11 to 83 years. Study
patients had a variety of cancer sites including head and neck
cancer, testicular cancer, gynecologic cancer, pulmonary cancer,
breast cancer, brain cancer, and other sites. Patients also received
concurrent cranial irradiation which may involve areas of inner
ear organs in brain, and head and neck cancers (12, 35–38).
Platinum-basedmedication reported in the included studies were
cisplatin, carboplatin, oxaliplatin, and non-specified platinum
compounds.
Thematic Analysis
From the data extraction and thematic analysis, five themes
were defined to determine areas of interest for an overview of
platinum-based vestibulotoxicity: (1) objective tests of vestibular
and/or balance function, (2) patients’ symptoms, (3) physical
examination, (4) associated factors such as dosage, pre-existing
vestibular loss, and accompanying cochleotoxicity, and (5)
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FIGURE 1 | Flow chart of stages of the study selection process.
general considerations. Results are presented according to these
themes.
Objective Tests of Vestibular and/or
Balance Function (N = 10)
Ten individual studies reported outcomes using one or more
objective vestibular or balance function tests (Table 1). Of these,
there were multiple publications based on the same study;
one reporting a prospective before and after study, plus three
corresponding case reports (12, 36–38), and another reporting
the same prospective before and after study in two publications
(42, 43). Other studies were four prospective before and after
studies (13, 39–41), and four cross-sectional studies (35, 44–46).
Almost all of these reports focused on toxicities from cisplatin.
From these 10 studies, several objective techniques to evaluate
vestibular or balance function were reported.
Objective tests for vestibular function included the caloric
test (12, 13, 36, 40, 41), rotational tests (13, 39–41), vestibular
autorotation test (VAT) (42, 43), and horizontal video head
impulse test (vHIT) (35). Details are given in Table 2. All
of these tests detect the horizontal VOR abnormalities. Most
studies reported a single vestibular function test such as the
caloric test (12, 36), VAT (42, 43), and vHIT (35). Three studies
evaluated both caloric and rotational tests (13, 40, 41). The
rate of abnormal findings detected by the caloric test after
chemotherapy administration varied between 0% (40), 2.9% (13),
4.2% (12, 36), and 50.0% (41). The rate of abnormal findings
detected by the rotational test after chemotherapy administration
ranged between 0% (40), 20.0% (41), 20.6% (13), and 31.2%
(39). Abnormal vestibular function, as detected by the vHIT,
was reported in 25.0% of survivors (35). Transient reduction of
vestibular function on testing was reported in three studies (13,
39, 40). Bilateral vestibular hypofunction was reported in studies
using the caloric test (12, 36) and vHIT (35), whilst some studies
did not report which side had the abnormal caloric responses
(13, 41). The rotational test and VAT were useful in detecting
bilateral vestibular impairment, but the relative contribution
could not be discriminated from the results (13, 39, 40, 42, 43).
Objective tests for balance function included the postural test
(39, 41), the Time Up and Go (TUG) test (45, 46), the Fullerton
Advanced Balance (FAB) scale (45, 46), and theModified Clinical
Test of Sensory Interaction on Balance (CTSIB-M) (44). Details
are given in Table 3. Two of these studies also assessed vestibular
dysfunction (39, 41). The abnormal rate of the postural test
after completion of chemotherapy treatment was 18.8% (39),
and 54.5% (41). Cancer survivors with chemotherapy-induced
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TABLE 2 | Examples of objective tests of vestibular function.
Test Pathway of testing Procedure Advantages Limitations
Caloric test VOR via horizontal SCC at
low frequency stimulus
(0.002–0.004 Hertz)
Cold and warm water or air are
irrigated into the external auditory
canal. Nystagmus is detected
and the two sides are compared.
- Localization, separate testing of
each ear
- Non-physiologic because of
relatively low frequency testing
- Can induce intense vertigo/dizziness
symptoms
- Bulky equipment
- More problematic in the
interpretation of bilateral vestibular
dysfunction
Rotational chair test VOR via horizontal SCC at
low-mid frequency stimulus
(0.01–0.7 Hertz)
Patient sits in a computerized
chair and wears video goggles.
Eye movements are recorded
during rotation of the chair.
- Useful for bilateral vestibular loss
- Can be performed in children
- Lack of localization
- Bulky equipment
Active head rotation
test (Autorotation test)
VOR via horizontal SCC at
mid frequency stimulus
(0.5–6 Hertz)
Eye movements are recorded
during active head movement in
synchrony with audio clicks of
different frequencies.
- Rapid assessment
- Patients can tolerate the test well
without uncomfortable feelings
- Portable equipment
- Lack of localization
- Compensatory mechanisms during
active head movement
Video head impulse
test (vHIT)
VOR via all six SCC at high
frequency stimulus (4–7
Hertz)
Patient sits on a chair and is
instructed to stare at a target on
the wall. Equipment to record
head movements and video
goggles are placed. The quick
and unpredictable head turn is
carried out by the tester.
- Canal and side specific
- Can detect covert saccade
(pathologic eye movement during
head movement)
- Rapid assessment
- Most people can tolerate the test
well
- Portable equipment
- Cannot perform in patients with
cervical spine problems
- Operator learning curve exists
- Expensive
Vestibular Evoked
Myogenic Potentials
(VEMPs)
1. oVEMP (Ocular)
2. cVEMP (Cervical)
Otolith organs
- Utricle
- Saccule
Loud sound is presented and
muscle activation, either at neck
or ocular muscles, is detected
through the surface electrodes.
- Rapid assessment
- Can be tested in patients with
sensorineural hearing loss
- Conductive hearing loss can
obliterate VEMPs
Source (47).
neuropathy (CIN) had significantly worse scores on both the
Time Up and Go (TUG) test and the Fullerton Advanced
Balance (FAB) scale (45, 46). Three out of fifty patients (6%)
who underwent cancer treatment during their childhood had an
abnormal score of CTSIB-M when long-term effects were tested
more than 10 years afterwards (44).
The testing interval varied amongst studies. Some studies
reported testing before each subsequent dose (12, 36, 40, 42,
43), one study tested at variably different time points (39), and
some studies did not specify the interval of testing (13, 41).
Cross-sectional studies assessed long-term side effects with no
availability of baseline comparison (35, 44–46).
Patients’ Symptoms (N = 74)
Seventy-four studies mentioned some forms of patient-reported
symptoms relating to possible vestibular or balance problems.
It is difficult to reliably distinguish vestibular from balance
dysfunction based on the symptoms alone (8). As a result,
symptoms are reported collectively. Terms used by study
authors to describe vestibular side effects are often used
interchangeably and nonspecifically, for instance, “dizziness”
includes “disequilibrium,” “lightheadedness,” and “vertigo”
according to the Common Terminology Criteria for Adverse
Events (CTCAE) (48). None of the included reports explicitly
clarified the definition of these terms which may lead to some
degree of ambiguity.
Most studies did not report on the methods used for
patient symptom evaluation such as spontaneous reports, patient
checklists, interviews or reports by the clinicians. The only study
that used a standardized patient-reported outcome questionnaire
was the study by Camet (44), which reported 21 out of fifty
pediatric cancer survivors (42%) with an abnormal score on the
Pediatric Vestibular Symptom Questionnaire (PVSQ).
Regarding the results of those studies with objective vestibular
function tests, the rate of reported vestibular symptoms varied
from 0% (13, 40, 42, 43) to 41.7% (35). Whilst some vestibular
impairment was detected by an objective test, patients did not
report any subjective sensation of vestibular disorder (13, 40,
42, 43). Vestibular symptoms reported were transient dizziness
(12, 36), unsteadiness (41), and vertigo (35). One patient had
compensated well for his vestibular loss, except in the dark (36).
Patients’ symptoms were not reported in one study despite a high
rate of abnormal vestibular test results (39).
Many examples were found of studies where patients
complained of symptoms that were potentially due to vestibular
side effects, but without verification by objective measurement.
Studies in cancer treatment involving multiple medications
including platinum-based drugs have reported non-specific
balance symptoms such as dizziness, vertigo, ataxia, balance
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TABLE 3 | Examples of objective tests of balance function.
Test Pathway of testing Procedure Advantages Limitations
Postural test
(Posturography)
- Both motor and sensory
balance system
- Vestibulo-cerebellar reflex
(VCR) pathway
Patient is instructed to stand in various
conditions such as on a fixed or moving
force plate with eyes open or closed.
- Isolate and quantify the
principal sensory inputs
- Quantitative results
- Limitation in some severely
ill people that cannot stand
without supports
- Expensive
- Bulky equipment
Modified Clinical Test of
Sensory Interaction on
Balance (CTSIB-M)
- Both motor and sensory
balance system
- Vestibulo-cerebellar reflex
(VCR) pathway
Patient is instructed to stand without
shoes with feet together and arm crossed
for up to 30 seconds in various conditions:
solid surface or on foam with eyes open or
closed. Time to complete the task is
recorded.
- Isolate and quantify the
principal sensory inputs
- Simple
- Screening test
- Less quantitative results
Time Up and Go (TUG)
test
Functional body balance by
testing performance-based
activities
Patient is instructed to stand from an
armed chair, walk 10 feet, turn, and return
to a seated position. Time to complete the
task is recorded.
- Simple
- Screening test
- Lack of localization
Fullerton Advanced
Balance (FAB) scale
Functional body balance by
testing performance-based
activities
Patient is instructed to do 10 tasks
comprised of standing with feet together
and eyes closed, reaching forward to
retrieve an object held at shoulder height
with an outstretched arm, turning 360
degrees to the right and left, stepping up
onto and over a 6-inch bench, tandem
walking, standing on one leg, standing on
foam with eyes closed, two-footed
jumping, walking with head turns, and
performing reactive postural control. The
ability to complete the tasks is scored.
- Simple
- Screening test
- Lack of localization
Source (47).
problems, and gait disturbance. A recent multi-center study
of 952 testicular cancer survivors receiving cisplatin-based
chemotherapy stated 9.3% overall new cases of dizziness, vertigo
or balance problems (49).
Physical Examination (N = 4)
Physical examinations were reported in four studies (35,
40, 41, 44). In the study by Kobayashi et al. (41), there
were reports of spontaneous nystagmus (nystagmus in resting
position without any stimulus) in seven out of 10 patients
(70%) and positional nystagmus (nystagmus in a specific head
position) in 6 out of 10 patients (60%). All three patients that
complained of dizziness had spontaneous nystagmus and two
of them had positional nystagmus. However, not all patients
who had spontaneous nystagmus complained of dizziness.
The optokinetic tests, Romberg’s tests, gait tests and stepping
tests remained normal in all 74 patients (40). The rate of
abnormal results of dynamic visual acuity (DVA) as a vestibular
screening test was 28% (44). Three out of twelve patients
(25%) diagnosed with brain cancer had an inability to walk
in tandem gait and two of them (16.6%) had gaze-evoked
nystagmus (35).
Associated Factors (N = 8)
Some associated factors of vestibulotoxicity mentioned in the
literature were dosage, pre-existing vestibular dysfunction,
and accompanying cochleotoxicity. Vestibular function was
reported to have declined with increasing dose of cisplatin
within each patient (39, 42, 43). However, the data reviewed
did not allow the identification of specific cumulative dose
thresholds associated with vestibular or balance impact.
There is some evidence to suggest that subjects with pre-
existing loss of vestibular function are more likely to get
cisplatin vestibular toxicity. Two of five patients (40%) with
prior abnormal vestibular function had additional vestibular
loss after the cessation of the treatment, whilst one out of
nine patients (11.1%) with prior normal vestibular function
developed vestibular toxicity after chemotherapy (39). The
only report of the histological verification showed severe
loss of hair cells in peripheral vestibular sensory organs,
including a crystalline spherical concretion composed of
calcium carbonate in the left posterior semicircular duct,
which is compatible with a positive finding of benign
paroxysmal positional vertigo (BPPV) (37, 38). This could
be either the underlying cause of dizziness or an incidental
finding.
Vestibular toxicity defined by an abnormal vestibular function
test was accompanied by cochlear toxicity (either hearing
impairment or tinnitus) in three studies (12, 35, 36, 41), whilst
no hearing loss was found in three patients with reduced caloric
and rotatory response in one report (40), and no hearing status
was stated in the other studies (13, 39, 42, 43). None of these
studies stated the temporal correlation of vestibular and cochlear
symptoms.
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General Considerations
By pooling together details of the data items, some of the general
considerations about development of relevant literature, and
treatment modalities for cancer emerge from the literature.
Development of Relevant Literature
Some preliminary studies were conducted in the 1980s followed
by few studies after that. Whilst the number of publications
has increased since the 2000s, the majority of these mentioned
symptoms that were possibly due to vestibular side effects.
A few studies explored vestibular-related long-term effects of
chemotherapy recently indicating a growing awareness and
interest from the research community of vestibular toxicity of
platinum-based chemotherapy.
Treatment Modalities for Cancer
Treatment options are determined by cancer sites and staging.
Multimodality treatment and combination of cytotoxic
medications are common for cancer treatment. Patients
also received concurrent cranial irradiation, which may involve
areas of inner ear organs especially in brain, and head and neck
cancers (12, 35–38). Vincristine, etoposide and bleomycin have
been co-administered for cancer treatment (42, 43). One of three
symptomatic patients also received an aminoglycoside antibiotic,
amikacin (35), which is a known vestibulotoxic medication
(17). Moreover, cisplatin, carboplatin, and oxaliplatin may have
different degrees of vestibulotoxicity due to drug components,
pharmacodynamics, and pharmacokinetics (50).
DISCUSSION
This scoping review explored issues related to the vestibular
effects of platinum-based chemotherapy in order to identify
established knowledge and research gaps which warrant further
research.
Conclusions Based on Established
Knowledge
Evaluation of vestibulotoxicity in the existing literature included
objective tests, findings of physical examination, and patient
reported symptoms. Tests for evaluation of vestibulotoxicity in
previous publications have been largely focused on low to mid
frequencies of horizontal semicircular canal testing, utilizing the
caloric test, rotational tests, and the VAT. VHIT, a relatively
new technique, was used to test function of the horizontal
semicircular canal at higher frequency stimulation in one recent
study (35). The existing information of vestibular toxicity in
the literature examined only the horizontal semicircular canal
which is one of five peripheral vestibular sensory organs. This
may be due to the feasibility of testing all potentially affected
organs, or the fact that sensory cells in the semicircular canals
are more sensitive to toxic medication than those in the otolith
organs (51).
Vestibular function loss may not be recognized until the
patient loses other cues from vision and somatosensory such as
when walking in the dark or develops concomitant peripheral
neuropathy. Balance function tests such as posturography,
testing overall balance system function in various conditions,
can provide additional information on balance in real life
and dynamic situations. Subclinical vestibular toxicity is a
concern because its effect may only be evident in patients with
other impaired sensory inputs, previous vestibular problems,
or it may lead to earlier onset of age-related vestibular
impairment (52).
The distinction between “objective tests of clinical signs”
that can be measured by the clinicians and “subjective
clinical symptoms” that can only be reported by the patients
should be emphasized. The existing literature showed that
objective test findings and patient symptoms did not always
correspond to one another. Multiple studies reported abnormal
vestibular function tests in asymptomatic patients (13, 40,
42, 43), therefore it is quite clear that clinicians cannot rely
solely on symptoms to detect vestibular toxicity. It is not
surprising that most patients did not have intense symptoms
due to the potential bilateral symmetrical insidious nature
of ototoxic medication. Symptoms such as vertigo, dizziness,
headache, nausea, double vision, photophobia, ataxia, and light-
headedness have previously been reported in patients with
bilateral vestibular impairment (53, 54). Balance symptoms such
as dizziness and unsteadiness are associated with vestibular
dysfunction; however, the relationship between vestibulotoxicity
and non-specific balance symptoms may not always be
clear.
Dizziness and other balance problems can be difficult to
describe for the patient and to categorize by the physician.
Hence, clarification of the terminology used is important for
the interpretation. These non-specific symptoms of balance
problems might automatically be associated with cancer
diseases and general deconditioning of patients. Comorbid
factors such as peripheral neuropathy, fatigue, and anemia,
including brain pathology in brain cancer patients can
cause some elements of postural unsteadiness in cancer
patients. Clinical symptoms are often underappreciated by
both patients and clinicians. For example, vestibular toxicity
may be a subtle complaint presenting as nausea, vomiting, or
dizziness, which are not uncommon in cancer patients receiving
chemotherapy.
Known risk factors of cochlear ototoxicity are aging, the
cumulative dose of chemotherapy, poor renal function, and
co-administration of other ototoxic medications (55). Possible
potential risk factors of vestibular toxicity identified in the
literature are cumulative dose and pre-existing vestibular loss.
Decreased vestibular function occurred as cumulative dose of
cisplatin increased, which supports the assumption of dose-
related response (39, 42, 43). There is some evidence to tentatively
support that patients with pre-existing loss of vestibular function
are prone to cisplatin vestibular toxicity, for instance, the
additional loss of vestibular impairment also occurred in patients
with previous abnormal vestibular function (12, 36, 39).
Knowledge Gaps
The rate of abnormal vestibular function test findings associated
with platinum-based chemotherapy in the existing literature
varied from 0 to 50% after chemotherapy treatment and
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4.3–36.5% during chemotherapy pathway. These should be
viewed as preliminary reports due to variable methodology,
limited reported information and the relatively small number of
patients. Therefore, the incidence and prevalence of vestibular
abnormality after platinum-based chemotherapy warrant further
research.
None of the studies evaluated vestibular function using vHIT
to test all six semicircular canals, nor vestibular evoked myogenic
potentials (VEMPs) to test otolith organs. A single test may
not be a good indicator of the true vestibular function and
findings from a comprehensive vestibular test battery have
not been yet reported. Limitations of vestibular and balance
function tests are summarized in Tables 2, 3. The current review
gleaned sparse information and details on the procedure of the
physical examination. Baseline testing is required to evaluate
prior vestibular impairment and to detect subtle changes. Based
on the existent information, data on affected sites of lesions
in vestibular end organs, and the impact on higher frequency
function associated with vestibulotoxicity in clinical studies is still
lacking.
Most of the included reports did not mention the methods
used for patient symptom evaluation. The approaches utilized
in detecting or monitoring adverse effects, such as spontaneous
reporting, patient checklist, questionnaire, diary, systematic
survey of patients or report by the investigators, are known to
have an influence on the frequencies of adverse effects identified
(56). For example, passive monitoring based on spontaneous
reports might yield lower rates of adverse events, while active
surveillance using specific questioning could find a higher
rate.
The association between cochlear impairment and vestibular
toxicity is still unknown. Cochlear function deficit is more
frequently described in the literature (4), potentially because it is
more common, or it is recognized earlier and before vestibular
impairment, symptoms of which tend to occur after complete
bilateral loss or asymmetrical loss (14).
BPPV is common in the general population, including
subjects receiving ototoxic drugs (57). BPPV presenting
in subjects receiving ototoxic drugs may complicate the
clinical identification of ototoxicity and obscure the clinical
decision. Nevertheless, the possible role of ototoxicity
in the pathophysiology of BPPV was not clear from the
literature.
A combination of treatments is common in cancer treatment
so evaluating the relationship between platinum-based
chemotherapy and vestibulotoxicity may not be straightforward.
Vestibulotoxic medications such as aminoglycoside antibiotics
(17) are sometimes used to cure infections in cancer patients.
Although most chemotherapeutic agents are not classified
as ototoxic medication, vincristine (58) and bleomycin (59)
have been shown to cause cochlear hair cell damage in in
vivo studies. It has also been postulated that platinum-based
chemotherapy and radiotherapy have a combination of effects on
cochleotoxicity (60, 61). Currently, there is limited information
not only on platinum-based chemotherapy but also other
treatment modalities and their combinations which should be
taken into account in data interpretation.
Limitations of the Study
At present, there are methodological limitations in the
published literature about vestibular effects of ototoxic
medications. Some limitations of the current review are
that a significant portion of included studies reported
limited information, and only publications in the English
language were included; thus, language bias may have
occurred.
CONCLUSION
A number of studies reported significant evidence of cisplatin
vestibular toxicities with objective tests, although not always
corroborated by patient symptoms. Multiple studies also
reported non-specific imbalance symptoms which are possible
complaints of vestibular dysfunction; however, the nature of
these symptoms is unclear without any objective test. There was
very limited clinical research data to date on the vestibular side
effects of platinum-based chemotherapy in terms of incidence,
evaluation and impact on health-related quality of life of the
patients. The data of physical examination was reported in
only a few studies and was not comprehensive. The current
evidence was based solely on the horizontal semicircular canal
evaluation using the caloric tests or rotational tests; therefore, the
information of vertical semicircular canals and otolith organs is
still lacking.
In conclusion, this scoping review summarizes the current
research findings that vestibular toxicity needs more attention
and emphasizes the need for future high-quality studies in
this field. Comprehensive evaluation of vestibular toxicities,
identifying risk factors such as cumulative dose, pre-existing
abnormal vestibular function and aging, including the correlation
with cochlear toxicity and peripheral neuropathy warrant further
research. Another challenge tends toward which test would
be the most sensitive and appropriate for early detection and
monitoring changes before, during and after platinum-based
chemotherapy treatment.
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